
    
      To evaluate the retinal and optic nerve functions of bevacizumab when injected intravitreal
      in human eyes using electrophysiological tests; Electroretinogram (ERG) and Visual Evoked
      Potentials (VEP). Forty five eyes of 45 patients with choroidal neovascular membrane (CNV)
      who were prepared for intravitreal injections of 1.25mg bevacizumab underwent baseline ERG
      and VEP in both eyes before, and at 1 and 4 weeks after the intravitreal injections.
    
  